Boehringer Ingelheim Partnering Day

Boehringer Ingelheim
Areas Of Interest
Cardiometabolic Diseases

Apply for 1-on-1 Meeting

Plenary Session Registration
please complete information below

Working Together for Better Health.

Boehringer Ingelheim is a global pharmaceutical company headquartered in Germany. In every aspect of our work, Boehringer Ingelheim strives to collaborate for the better health of patients worldwide. We focus our efforts in five major therapeutic areas: cardiometabolic diseases, central nervous system diseases, immunology and inflammation, oncology and respiratory diseases.

We encompass opportunities across the entire drug discovery and development value chain by: 1) focusing on the discovery and development of new and/or better medications for patients in our areas of therapeutic focus and 2) identifying and exploring new therapeutic concepts. Scientists at our fully integrated drug discovery centers of excellence have extensive capabilities in both small molecules and biotherapeutics and are working with academic and corporate partners to discover new treatments to address continually evolving unmet medical needs.

We believe in long-term partnerships that create a culture for future shared commercial success. Our loyalty to our partners and enthusiasm for their projects is evidenced by the number of ‘repeat’ business transactions that have taken place. Seeking to create an environment that fosters scientific collaboration and trust is important for our partnerships in order to work together with you and facilitate its success.

We are enthusiastic to work with you, providing capabilities to complement your expertise, so together we can achieve success and deliver better therapies for patients.

Confirmed Boehringer Ingelheim Participants:
Dr. Paola Casarosa – Corporate VP, Therapeutic Alliances and Strategic Partnerships
Dr. Monica Cheng – Cardiometabolic Diseases Business Development and Licensing
Dr. Laurie Churchill – Global Head Immunology Business Development and Licensing
Dr. Jay Fine – VP, Immunology Research
Dr. Christine Grygon – Executive Director, Business Development and Licensing
Dr. Iaonnis Sapountzis – Global Head Oncology Business Development and Licensing
Dr. Margrit Schwarz – VP, Cardiometabolic Research
Dr. Clive Wood – Corporate Head of Research


Boehringer Ingelheim Partnering Day


Wednesday, October 15, 2014
(application required) (by invitation)
10-11am | Immunology Roundtable
11am-12pm | Cadiometabolic Roundtable
12-1pm | Oncology Roundtable
Boehringer Ingelheim: Partner of Choice and Corporate Overview
(open to life science companies only)
1:30-2:00 | BI Corporate/R&D overview, Partnering presentation
2:00-3:00 | Moderated panel discussion with TA heads
3:00-3:30 | Moderated panel discussion with deal partners
(open to life science companies only)


Hyatt Regency San Francisco Airport
1333 Bayshore Highway
Burlingame, CA, 94010



  • Early registration is highly advised as space is limited and there will be no on-site registration
  • Pre-registered attendees will receive an immediate receipt/confirmation after submission
  • Please print this receipt/confirmation and bring it with you to receive your conference credentials
  • Photo ID (driver’s license or passport) will be required at check-in
  • All sales are final

Please mail your event-related questions to: or you can contact us via phone: 650-871-3257.

Is your company a member? Click here to check.
See how your company can save money by becoming a BayBio member!